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404Background: We reported the outcomes of a single-institution experience using video-assisted thoracoscopic
left cardiac sympathetic denervation as an adjunctive therapeutic technique in pediatric and young adult patients
with life-threatening ventricular arrhythmias.
Methods:We conducted a retrospective clinical review of all patients who underwent left cardiac sympathetic
denervation by means of video-assisted thoracoscopic surgery at our institution. From August 2000 to
December 2011, 24 patients (13 with long QT syndrome, 9 with catecholaminergic polymorphic ventricular
tachycardia, and 2 with idiopathic ventricular tachycardia) were identified from the cardiology database and
surgical records.
Results: There were no intraoperative complications. The median postoperative length of stay was 2 days
(range, 1-32 days). There were no major perioperative complications. Longer-term follow-up was available
in 22 of 24 patients at a median follow-up of 28 months (range, 4-131 months). Sixteen (73%) of the 22 patients
experienced a marked reduction in their arrhythmia burden, with 12 (55%) becoming completely arrhythmia
free after sympathectomy. Six (27%) of the patients were nonresponsive to treatment; each had persistent symp-
toms at follow-up.
Conclusions: Video-assisted thoracoscopic left cardiac sympathetic denervation can be safely and effectively
performed in most patients with life-threatening ventricular arrhythmias. This minimally invasive procedure
is a promising adjunctive therapeutic option that achieves a beneficial response in most symptomatic patients.
These results support the inclusion of thoracoscopic cardiac sympathetic denervation among the treatment
armamentarium in all patients with ventricular arrhythmias refractive to conventional medical therapy. (J Thorac
Cardiovasc Surg 2014;147:404-11)The sympathetic nervous system plays a prominent role in
the genesis of many life-threatening ventricular arrhyth-
mias. b-Blockade is the mainstay of therapy; however,
despite reducing arrhythmia frequency, many patients expe-
rience persistent cardiac events and remain at risk of sudden
death.1,2 Intolerance to antiarrhythmic agents is also a
common problem.1 In some patients, a more aggressive
strategy to prevent sudden cardiac death is required.
Implantable cardioverter-defibrillator (ICD) implantation
has frequently been used in these cases. Although ICDs
effectively protect against lethal arrhythmias, associated
morbidities are prominent and include procedural risks, de-
vice malfunction, inappropriate shocks, and psychologicale Departments of Cardiac Surgerya and Cardiology,b Boston Children’s Hos-
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The Journal of Thoracic and Cardiovascular Surgdistress, particularly among adolescents.3 Left cardiac sym-
pathetic denervation (LCSD), first described in 1971,4 has
been a safe and effective procedure to reduce fatal arrhyth-
mias and prevent cardiac death. The surgical technique has
undergone several modifications,5 with variations in strat-
egy among different centers.
Video-assisted thoracoscopic (VATS) LCSD was first re-
ported by Reardon and colleagues6 in 2000, with Li and col-
leagues7 reporting the first small series in patients with
LQTS in 2003. Several groups have demonstrated positive
intermediate outcomes using adjunctive thoracoscopic
LCSD to treat intractable ventricular arrhythmias in pediat-
ric patients,8-11 with the largest experience in children
with refractory LQTS (long QT syndrome).8-10,12 The
indications for performing VATS-LCSD continue to evolve,
with recent reports demonstrating its utility in children with
non-LQTS arrhythmias.2,8,12 Herein, we report our single-
center experience performing adjunctive VATS-LCSD in
24 pediatric and young adult patients with life-threatening
ventricular arrhythmias.PATIENTS AND METHODS
This retrospective study was performed after approval from the Institu-
tional Review Board. Patients were identified using the cardiology database
and surgical notes. Medical records were reviewed for baselineery c January 2014
Abbreviations and Acronyms
CPVT ¼ catecholaminergic polymorphic
ventricular tachycardia
ICD ¼ implantable cardioverter-defibrillator
IVT ¼ idiopathic ventricular tachycardia
JLNS ¼ Jervell and Lange-Nielsen syndrome
LCSD ¼ left cardiac sympathetic denervation
LQTS ¼ long QT syndrome
VATS ¼ video-assisted thoracoscopic
VF ¼ ventricular fibrillation
VT ¼ ventricular tachycardia
Hofferberth et al Congenital Heart Diseasecharacteristics, treatment indications, details of operative strategy, intrao-
perative events, and postoperative course. Between August 2000 and
December 2011, VATS-LCSD was performed in a total of 24 patients
(11 males; median age, 13 years; range, 5 weeks to 27 years) at Boston
Children’s Hospital (Boston, Mass). The cohort includes the 9 patients in
our initial study from 2008 reporting the VATS-LCSD technique.8 Thirteen
were diagnosed with congenital LQTS (2 had Jervell and Lange-Nielsen
syndrome, defined as severe QT prolongation and congenital hearing
loss), 9 with catecholaminergic polymorphic ventricular tachycardia
(CPVT), and 2 with idiopathic recalcitrant ventricular tachycardia (VT).C
H
DSurgical Technique
In all patients, LCSDwas performed via a left-sided VATS approach un-
der general anesthesia. The operative technique is largely unchanged from
that described previously,8 with the following exceptions: dissection is per-
formed using a harmonic scalpel in place of electrocautery, and chest tube
placement in the left pleural cavity is no longer undertaken. The stellate
ganglion was intentionally spared in 23 of the 24 patients.Patient Descriptions
Long QT syndrome. Thirteen patients were identified with LQTS
(Table 1). The median age at LCSD was 8 years (range, 2-22 years). Six
(patients 1, 2, 4, 5, 6, and 8; Table 1) of the 13 had undergone previous
ICD implantation. Indications for LCSD included delivery of recurrent
appropriate ICD shocks despite optimal antiarrhythmic therapy in 4
(patients 4, 5, 6, and 8), ongoing arrhythmic events despite optimal antiar-
rhythmic therapy in 4 (patients 9, 11, 12, and 13), failed medical therapy
(unable to tolerate b-blocker dose increase) in 3 (patients 1, 2, and 3),
with 2 (patients 7 and 10) high-risk patients treated prophylactically. Of
the 13 patients, 9 had available genotypic information: 7 were LQTS-1
and 2 were LQTS-2 genotype.
Catecholaminergic Polymorphic VT. Nine patients were
identified with CPVT (Table 1). The median age at LCSD was 17 years
(range, 8-27 years). Seven had prior ICD implantation, with 1 (patient
19) also receiving a dual-chamber pacemaker. Delivery of recurrent ICD
shocks despite optimal medical therapy was the indication for LCSD in
6 of these 7 patients. Patient 17 had recurrent ICD shocks associated
with failure to tolerate medical therapy. The remaining 2 (patients 14
and 21) were symptomatic despite optimal medical therapy.
Intractable VT. Two patients (patients 23 and 24) had intractable VT.
Both had persistent symptoms despite optimized medical therapy. Patient
23 had recurrent VT despite maximal antiarrhythmic therapy and multiple
electrophysiology studies for ablation of a left-sided accessory pathway
and 3 distinct VT foci. Follow-up was limited to the time of discharge,
and he had ongoing runs of VT during a prolonged postoperative hospitalThe Journal of Thoracic and Castay. Patient 24 was treated at 5 weeks of age in the setting of recalcitrant
ventricular arrhythmias requiring repeated defibrillation.
RESULTS
Left Cardiac Sympathetic Denervation and
Video-Assisted Thoracoscopic Surgery
Video-assisted thoracoscopic LCSDwas performed in 24
patients. Eight patients received concomitant ICD implan-
tation; 1 received a dual-chamber pacemaker. There were
no intraoperative complications, and blood loss was mini-
mal. Continuous cardiac rhythm monitoring (telemetry)
was used in all patients postoperatively, with a pediatric
electrophysiologist reviewing the telemetry twice daily.
Two (9%) of the patients experienced arrhythmias before
discharge. Patient 2 developed VT necessitating cardiover-
sion and began taking esmolol and magnesium infusion. No
further arrhythmic episodes occurred. Patient 17 experi-
enced recurrent runs of VT, which led to a prolonged hospi-
tal stay of 32 days.
There were no major postoperative complications. Minor
postoperative complications occurred in 3 (13%) of the pa-
tients. Patient 16 developed a small apical pneumothorax,
necessitating chest tube suction. She was discharged 1
day later. Patient 18 developed a small left apical pneumo-
thorax and was successfully treated with 24 hours of oxygen
therapy. Her length of stay was 2 days. Patient 8 developed
prominent harlequin facial flushing, but not Horner syn-
drome, and this had resolved at follow-up. She is the only
patient to have had the left stellate ganglion included in
the LCSD. No patients developed Horner syndrome. Eleven
patients were initially managed in the postoperative inten-
sive care unit (ICU). The median length of postoperative
hospital stay was 2 days (range, 1-32 days).
Follow-up Outcomes
Long QT syndrome. Of the 13 patients with LQTS, 4 were
treated with LCSD for recurrent appropriate ICD shocks
despite optimal medical therapy. Of the 4 patients, 2 were
symptom free post-LCSD. Patient 4 was event free at 33
months, whereas patient 8 had complete resolution of her
frequent VT episodes at 131 months post-LCSD treatment
(Table 2). One patient (patient 5) demonstrated some reduc-
tion in arrhythmia burden. She experienced multiple ICD
discharges in the months before LCSD, and at latest
follow-up, she had experienced 2 further ICD firings and
required 4 antiarrhythmic medications. The fourth patient
treated for recurrent ICD discharges (patient 6) did not
respond to LCSD, experiencing ongoing recurrent ICD
shocks at 23months. In the 4 patients whowere symptomatic
despite optimal medical therapy, patients 11 and 12 were
both asymptomatic and required no antiarrhythmic therapy
at 31- and 29-month follow-up, respectively. Patient 13
experienced 2 ICD shocks during 13 months of follow-up,
although this occurred in the setting of poor medicationrdiovascular Surgery c Volume 147, Number 1 405
TABLE 1. Patient baseline characteristics
Patient no. Sex Age, y Diagnosis Initial presentation
Antiarrhythmic
medication(s)
Daily dose,
mg/kg Indication for LCSD
1 M 22 LQTS Syncopal episodes with VT Nadolol NA Multiple ICD shocks, unable to
tolerate medication increase
2 F 22 LQTS VF arrest Labetalol 7.6 Multiple ICD shocks, unable to
tolerate medication increase
3 F 19 LQTS Single syncopal episode Betaxolol 0.2 Failed medical therapy
4 F 22 LQTS Syncopal episodes with VT Labetalol 3.7 Multiple recent ICD shocks,
optimal medical therapy
Nadolol 1.1
5 F 15 LQTS Recurrent VT/TdP Labetalol 16.0 Recurrent VT, maximal medical
therapy
Nadolol 0.8
6 M 4 LQTS VT NA NA Multiple ICD shocks for VT, on
optimal medical therapy
7 M 4 LQTS (JLN) Asymptomatic Atenolol NA Primary prevention
8 F 6 LQTS (JLN) Recurrent TdP Nadolol 2 Multiple ICD shocks for TdP
9 M 3 LQTS Aborted SCD Propranolol 2.5 Multiple aborted SCDs despite
optimal medical therapy
10 F 2 LQTS Aborted SCD Nadolol 0.8 Primary prevention
11 M 10 LQTS TdP, cardiac arrest Esmolol 0.4 Frequent VT/TdP, symptomatic
despite optimal medical
therapy
12 M 8 LQTS Repeated episodes of LOC Nadolol NA Symptomatic despite medical
therapy
13 F 2 LQTS Aborted SCD with VT Nadolol 2.8 Recent VT arrest
14 M 21 CPVT Polymorphic VT Betaxolol 1.6 Symptomatic on optimal
medical therapy
15 M 15 CPVT VT, syncopal episodes Atenolol 0.8 Multiple ICD shocks, on
optimal medical therapy
16 F 19 CPVT Aborted SCD and VT Atenolol 2.1 Multiple ICD shocks, on
optimal medical therapy
17 M 11 CPVT VT Nadolol 1.5 Multiple AICD shocks for VT,
poor medication tolerance
18 F 15 CPVT Family history, asymptomatic Atenolol 0.8 Multiple ICD shocks for VT, on
optimal medical therapy
19 F 27 CPVT Exercise-induced syncope, VT Labetalol 6.3 Multiple ICD shocks for VT,
optimal medical therapy
20 M 17 CPVT VF arrest NA NA Multiple ICD shocks for VT/VF
with optimal medical therapy
21 F 8 CPVT Syncopal episode Nadolol 1.2 Symptomatic despite optimal
medical therapy
22 M 17 CPVT Exercise-induced syncope, VT Nadolol 2.4 Persistent ICD shocks for VT,
optimal medical therapy
23 M 2 IVT Syncopal episodes with VT Esmolol NA Intractable VT despite multiple
ablations, medical therapy
24 F 5 wk IVT VT, aborted SCD with VF Amiodarone NA Symptomatic despite optimal
medical therapy
LCSD, Left cardiac sympathetic denervation; LQTS, long QT syndrome (without congenital deafness); VT, ventricular fibrillation; NA, not available; ICD, implantable
cardioverter-defibrillator; VF, ventricular fibrillation; TdP, torsades de pointes; JLN, Jervell Lange-Nielson–type LQTS; SCD, sudden cardiac death; LOC, loss of consciousness;
CPVT, catecholaminergic polymorphic ventricular tachycardia; AICD, automatic implantable cardioverter defibrillator; IVT, idiopathic ventricular tachycardia.
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Dcompliance. This patient had experienced a ventricular
fibrillation (VF) arrest and multiple runs of VT in the
months preceding LCSD intervention. Patient 9 was lost
to follow-up. The 3 (patients 1, 2, and 3) treated with
LCSD after failing medical therapy were all asymptomatic406 The Journal of Thoracic and Cardiovascular Surgat latest follow-up, with patients 1 and 4 not requiring any
antiarrhythmic medications. Of the 2 (patients 7 and 10)
treated prophylactically with LCSD and concomitant ICD
implantation, patient 7 had experienced 3 ICD shocks and
was being managed on a single antiarrhythmic agent at 82ery c January 2014
TABLE 2. Patient outcomes
No. QTc before/after, ms Hospital stay, d Follow-up, mo Response to LCSD therapy
1 467/460 1 4 No events, no medications
2 467/422 4 37 No events, tolerating 3 antiarrhythmic agents
3 472/497 1 27 Asymptomatic, no medications
4 520/537 1 33 No events, 2 antiarrhythmic agents
5 542/560 1 11 2 ICD firings/year, 4 antiarrhythmic agents
6 392/479 1 23 Multiple ICD shocks/year, 2 antiarrhythmic agents
7 535/515 5 82 3 events in 6 years, 1 low-dose antiarrhythmic
8 630/588 2 131 No ICD shocks, 2 antiarrhythmic agents
9 476/456 5 1 NA
10 462/NA 4 26 6 episodes of TdP, increased antiarrhythmic
11 600/500 6 31 Asymptomatic, no medications
12 600/503 3 29 Asymptomatic, no medications
13 566/530 2 13 2 ICD shocks, 1 antiarrhythmic agent
14 461/421 1 13 No events, 2 antiarrhythmic agents
15 394/364 1 39 1 ICD firing/year, 1 antiarrhythmic agent
16 433/410 2 37 No events, 1 antiarrhythmic agent
17 422/399 1 47 1 ICD firing/year, 1 antiarrhythmic agent
18 419/NA 2 51 No events, medications unknown
19 403/412 2 7 No events, 3 antiarrhythmic agents
20 447/463 2 34 3 events in 3 years, 2 antiarrhythmic agents
21 399/NA 1 12 Asymptomatic, 1 antiarrhythmic agent
22 360/372 1 15 No events, 1 antiarrhythmic agent
23 506/NA 32 1 NA
24 440/396 3 46 No events, 2 antiarrhythmic agents
The mean SDQTc, before/after, is 476 72/465 61 ms.QTc, corrected QT interval; LCSD, left cardiac sympathetic denervation; ICD, implantable cardioverter-defibrillator;
NA, not available; TdP, torsades de pointes.
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Dmonths. Patient 10 experienced 6 episodes of torsades de
pointes and required increasing b-blockade at 26 months
post-LCSD (Table 2).
Catecholaminergic polymorphic VT. Of the 9 patients
with CPVT, 6 underwent VATS-LCSD for recurrent appro-
priate ICD shocks despite optimal antiarrhythmic therapy.
Patients 16, 18, 19, and 22 had no further ICD shocks at
37, 51, 7, and 15 months’ follow-up, respectively (Table
2). Of the remaining 2 patients with this indication, patient
15 averaged 1 ICD shock per year and was managed on 1
antiarrhythmic agent at 39 months post-LCSD. Patient 20
experienced 1 ICD shock per year over 34 months, with sta-
ble doses of 2 antiarrhythmic agents. Two patients (patients
14 and 21) underwent LCSD for persistent symptoms
despite optimal medical therapy; both were asymptomatic
at 13 and 12 months, respectively. In 1 (patient 17),
LCSD was indicated in the setting of recurrent ICD shocks
with failure to tolerate escalating b-blockade. At 47 months
post-LCSD, he averaged 1 ICD shock per year, and was be-
ing treated with a single antiarrhythmic agent.
Intractable VT. Two patients with idiopathic ventricular
tachycardia (IVT) were treated with LCSD and concomi-
tant ICD implantation for persistent symptoms despite
optimal medical therapy. Patient 23 was lost to follow-up,
whereas patient 24 was event free at 46 months post-
LCSD procedure.The Journal of Thoracic and CaOverall Response to LCSD Therapy
Longer-term follow-up was available in 22 of the 24
patients at a median of 28 months (range, 4-131 months).
Two patients referred from overseas centers were lost to
follow-up. In 10 (4 LQTS and 6 CPVT) patients, the indi-
cation for LCSD was recurrent ICD shocks despite
optimal medical therapy. Of these patients, 8 (80%)
experienced a marked reduction in their arrhythmia
burden after LCSD, with 6 (60%) becoming arrhythmia
free.
Longer-term follow-up was available in 6 of the 8 (4
LQTS, 2 CPVT, and 2 IVT) patients who were symptom-
atic despite optimal medical therapy before LCSD proce-
dure. Five patients (83%) had a marked reduction in
arrhythmia burden, whereas 4 (66%) were arrhythmia
free. Patient 22 (LQTS) had 2 ICD shocks in the first
year post-LCSD, necessitating an escalation of antiar-
rhythmic therapy.
Four patients (3 LQTS and 1 CPVT) received LCSD after
failing to tolerate medical therapy. Three patients (75%)
had a marked reduction in arrhythmia burden; 2 were
arrhythmia free and no longer required medical therapy,
whereas 1 was able to tolerate lower doses of antiar-
rhythmic agents while remaining asymptomatic.
Of the 2 patients who received LCSD therapy as a pro-
phylactic measure, 1 had 3 arrhythmic events over 6 yearsrdiovascular Surgery c Volume 147, Number 1 407
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Dof follow-up, whereas the other appeared to only marginally
benefit from the LCSD. This patient had recurrent arrhyth-
mias and required escalation of medical therapy during the
available 2-year follow-up period.
DISCUSSION
Video-assisted thoracoscopic LCSD is becoming
increasingly recognized as a safe and effective adjunctive
therapy in patients with life-threatening ventricular arrhyth-
mias.8-10,12 Herein, we describe our single-center experi-
ence using the minimally invasive VATS-LCSD approach
in children and young adults with malignant ventricular ar-
rhythmias. Of the 24 patients in this cohort, 13 had LQTS
(including 2 patients with Jervell and Lange-Nielsen syn-
drome) and 9 had CPVT, with 2 diagnosed with idiopathic
VT. Patient selection for LCSD therapy consisted of 3 sub-
groups of patients, presenting with 1 of 3 characteristics:
persistent symptoms (defined as recurrent appropriate
ICD shocks despite optimal medical therapy or arrhythmic
events, despite optimal medical therapy), failure to tolerate
medical therapy, or prophylactic therapy. The absence of
procedure-related complications, and minimal (n ¼ 3) inci-
dence of mild/transient postoperative complications, is
consistent with previous reports8,9 using the minimally
invasive VATS-LCSD approach. Overall, we demonstrate
VATS-LCSD is a low-morbidity procedure that achieves a
marked response in most patients with symptomatic life-
threatening arrhythmias, irrespective of underlying arrhyth-
mogenic etiology.
Left Cardiac Sympathetic Denervation and
Video-Assisted Thoracoscopic Surgery
Left cardiac sympathetic denervation was initially
described by Moss and McDonald4 in 1971 to treat patients
with medically refractory LQTS. Animal and human
studies, performed soon thereafter, suggested left cardiac
sympathetic nerves are proarrythmogenic, because the ven-
tricular refractory period was prolonged and fibrillation
thresholds increased after stellate ganglia denervation.13,14
Stimulation of the left stellate ganglion has also triggered
T-wave alternans, which is frequently associated with
LQTS.13-15 Because LCSD involves both preganglionic
and postganglionic denervation, postoperative
supersensitivity and reinnervation are unlikely to occur,
thereby ensuring the antifibrillatory effects are permanent.
Permanence is important in the context of poor
medication compliance, an issue of particular relevance in
the adolescent population. With greater understanding of
its antifibrillatory properties, LCSD has emerged as a safe
adjunctive therapeutic option for patients with ventricular
arrhythmias refractory to standard therapy.5,9,16 The
largest experience is a multicenter series reporting more
than 80% reduction in cardiac events post-LCSD in 147
patients with LQTS.5408 The Journal of Thoracic and Cardiovascular SurgThe LCSD procedure has undergone several modifica-
tions since it was first described. Variations in surgical tech-
nique include high-thoracic left sympathectomy,13 left
cervicothoracic sympathectomies (stellate ganglion and up-
per thoracic ganglia), bilateral sympathectomies, and a pos-
terior approach.17-19 Since VATS-LCSD was first reported
by Reardon and colleagues6 in 2000, several small series
have used the technique in pediatric patients with intrac-
table ventricular arrhythmias.8-11 Most of the global
experience has been in patients with refractory LQTS.
Nearly 80% of all reported cases using VATS-LCSD in pa-
tients with LQTS demonstrate resolution of arrhythmias/
symptoms at 1 year.8-11 Similarly, it has effectively
treated CPVT.8,9,12,16 A smaller experience exists in
patients with Jervell and Lange-Nielsen syndrome
(JLNS), a more malignant autosomal recessive variant of
congenital LQTS, that is associated with deafness.
Because of the severity of this phenotype, pharmacologic
therapy alone is often inadequate and more aggressive
treatment is required.20 Both of the series that included pa-
tients with JLNS8,12 report a high response rate; in the study
by Coleman and colleagues,12 only 1 of 5 patients with
JLNS experienced a cardiac event post-LCSD. Two of the
patients in our initial series had JLNS; one achieved com-
plete resolution of symptoms, whereas the other experi-
enced 1 event at 26-month follow-up.8 These results are
not surprising given the marked response rate among pa-
tients with LQTS. Although fewer data are available for pa-
tients with IVT, it appears VATS-LCSD offers benefit to this
population also.8,12 Among all reported series undertaking
VATS-LCSD, procedural morbidity and surgical complica-
tion rates, including operative blood loss, have been mini-
mal.8-10,12 The outcomes of this study confirm that VATS
sympathectomy is a safe and feasible therapeutic option
that carries minimal procedural risk.
Indications for Treatment and Outcome of LCSD
Symptomatic patients. This report documents an overall
response rate of almost 80% in patients who were symp-
tomatic at LCSD intervention. Patients treated after experi-
encing multiple ICD discharges despite optimal medical
therapy, and those who had persistent symptoms despite
optimal medical therapy, received the most benefit from
adjunctive LCSD therapy.
Failure to tolerate medical therapy. In the 4 patients who
developed significant adverse effects at maintenance antiar-
rhythmic doses or who failed to tolerate escalating
b-blocker therapy, 3 appeared to benefit markedly. Perfor-
mance of adjunctive VATS-LCSD appears a promising
strategy to enable this patient subgroup to be maintained
at a lower medication dose and still remain symptom free.
Furthermore, for some of these patients, adjunctive LCSD
may eliminate the requirement for ongoing antiarrhythmic
therapy altogether.ery c January 2014
Hofferberth et al Congenital Heart DiseaseAsymptomatic, primary prevention. Two patients
(patients 13 and 18) in this cohort underwent
VATS-LCSD as a prophylactic measure. The outcomes
were equivocal as to whether any real benefit was derived
from undergoing the procedure. With such limited experi-
ence and indeterminate results, our data do not support un-
dertaking prophylactic VATS-LCSD in all children
identified at high risk of fatal arrhythmias. Nevertheless,
there may be a subset of patients who possess a high-risk
genotype that would benefit from prophylactic LCSD treat-
ment. A recent study by Jons and colleagues21 demon-
strated that analysis of mutant-specific ion channel
characteristics in LQTS patients may be useful for clinical
risk stratification. Further investigation may reveal a spe-
cific genotype and phenotype that are associated with a
heightened risk profile and would, therefore, benefit from
adjunctive VATS-LCSD as a primary preventative strategy.
Nevertheless, we cannot recommend LCSD as a prophylac-
tic therapy.C
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DCONCLUSIONS
In summary, we have documented that video-assisted
thoracoscopic LCSD can be safely and effectively per-
formed in most children and young adults with life-
threatening ventricular arrhythmias. This minimally
invasive procedure is a promising adjunctive therapeutic
option that achieves a beneficial response in most symptom-
atic patients. We advocate the use of this treatment in all
patients who remain symptomatic with recurrent life-
threatening arrhythmias, syncope, or frequent ICD
discharges, despite conventional medical therapy. This
treatment strategy should be considered as part of the treat-
ment armamentarium in all patients with recalcitrant
ventricular arrhythmias. The utility of LCSD as a prophy-
lactic therapy in high-risk pediatric patients must be further
elucidated before definitive recommendations can be made.References
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Dr Joseph Dearani (Rochester, Minn). Thank you, Dr Backer
and Dr Reddy.
Dr Hofferberth and colleagues have summarized their results of
a small series of 24 children with VATS sympathetic denervation
to treat life-threatening ventricular arrhythmias. Their technique
intentionally spares the entire left stellate ganglion. They demon-
strated a ‘‘marked reduction’’ of arrhythmias in 73% and elimina-
tion of arrhythmias in 55%. Two were lost to follow-up, and 2 had
1-month follow-up; this should be factored into the recurrence
equation.
Surgery was performed safely; however, I believe there are
shortcomings with this review. Most centers with the greatest
experience in treating these cardiac channelopathies intentionally
remove the lower half of the left stellate ganglion. The literature
has demonstrated that the optimal cardiac denervation includes
the removal of T4, T3, T2, and the lower pole of the left stellate
ganglion (T1). In fact, the greatest density of norepinephrine-con-
taining vesicles resides in the stellate ganglion (T1) and a portion
of T2. So, ideally, cardiac denervation would include a completerdiovascular Surgery c Volume 147, Number 1 409
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Dstellectomy. However, the upper pole of the left stellate ganglion is
preserved to minimize the potential risk of developing Horner
syndrome.
Among the largest programs that perform this specific left car-
diac sympathetic denervation operation (ie, taking the lower half
of the stellate ganglion and T2 through T4), there exceeds a 90%
reduction in arrhythmia burden that includes breakthrough faints
and breakthrough ICD shocks overall. Furthermore, the antifibril-
latory (ie, protective effect) of denervation therapy is disease and
disease genotype dependent, where it has been shown to be most
effective in LQT1 and CPVT, emphasizing the importance of gen-
otyping for all of these patients. For example, among the greater
than 30 LQT1 patients denervated in our practice, there have
been no breakthroughs to date with longer follow-up. Unfortu-
nately, we do not know the genotypes of the long QT patients in
this small series. If many or most were LQT1, then the higher
observed breakthrough rate further underscores the critical impor-
tance of including the lower pole of the left stellate ganglion in the
operation.
I believe cardiac denervation surgery for channelopathies
should not be viewed as a simple adaptation of minimally invasive
surgery performed for hyperhidrosis, and it probably should not be
performed at a pace of approximately one procedure per year.
Despite performing approximately 20 per year, we still encounter
pretty variable anatomic variation with the left stellate ganglion. In
addition, in our experience, we have now performed left cardiac
sympathetic denervation in over 110 patients with these potentially
life-threatening disorders. In the early part of our reported series,
there were 3 patients with eyelid ptosis. Importantly, to date, there
is no patient with a complete Horner (facial droop), in more than
110 patients.
In closing, I agree with your VATS approach to sympathectomy,
and I congratulate your team for performing it with low periproce-
dural morbidity. However, I respectfully disagree with your tech-
nique to intentionally spare the left stellate ganglion, leaving up
to a third of your patients with residual ventricular arrhythmias, re-
sulting in ICD discharges. This study demonstrates that this tech-
nique is less effective for this difficult problem, and I would
encourage you to acknowledge this higher incidence in arrhythmia
recurrence when the lower half of the stellate ganglion is
preserved.
Dr Hofferberth. Thank you very much for your comments,
Dr Dearani.
First, I would like to address the issue of the indications for
treatment in this study. The vast majority of the literature that ex-
ists using the VATS-LCSD procedure is in patients with cardiac
ion channelopathies, who are treated for secondary prevention.
Looking at our data, we had a 73% response rate among all-comers
with 2 patients in the series of 24 treated for primary prevention. If
you exclude those 2 patients out, that means that we have an 82%
response rate among the patients that were treated for secondary
prevention.
Published data from other centers that perform the
VATS-LCSD technique certainly show that an 82% response
rate is equivalent to the results attained across the entire global
experience to date. There was a review article published 2 years
ago out of Texas Children’s Hospital by Hwang and colleagues,
who reviewed all cases using VATS-LCSD procedure in children410 The Journal of Thoracic and Cardiovascular Surgwith congenital long QT syndrome. This article demonstrated
that, of the global experience, there was a 77% response rate,
defined in terms of arrhythmia reduction. The vast majority of
data available on this topic defines response to treatment as
reduced arrhythmia burden. As I alluded to in the presentation,
it is difficult to quantify arrhythmia burden; however, that is a lim-
itation across all of the studies in this area. Nevertheless, based on
the current criteria for treatment response, our results are equal to
the global experience.
Dr Dearani. There is an important difference between a 90%
to 95% success rate, with ICD discharges going off in children
with refractory ventricular arrhythmias compared to 55% to
70%. This is an evolving science. Genotyping has helped under-
stand expectations in abolishing arrhythmias substantially. We
have not had a single case of a permanent Horner syndrome
with facial droop in over 100 cases when the lower pole of the
stellate is removed. Life-threatening ventricular arrhythmia
recurrence, resulting in ICD discharge, is different than recur-
rence of atrial fibrillation. It is a truly life-threatening problem,
and striving for a 90% to 95% arrhythmia reduction rate without
causing complete Horner syndrome seems to be a better goal to
aim for.
It would be helpful for other surgeons in the audience to
comment. As we discussed earlier, general pediatric surgeons
and pediatric cardiac surgeons do this procedure. It is important
that the surgical community understand the differences and expec-
tations with the various sympathectomy techniques.
Dr Hofferberth. Thank you, Dr Dearani. Our institution does
not agree with the notion that removal of part or all of the left stel-
late ganglion is a morbidity-free approach. The most recent article
published out of the Mayo Clinic in 2012, which described their
experience performing VATS-LCSD with resection of the lower
half of the left stellate ganglion, demonstrates this is not a
morbidity-free approach, with just over 10% of patients devel-
oping a perioperative Horner syndrome.
There was also an article published last month by Schneider and
colleagues from a center in Munich, who reported their results per-
forming LCSD with resection of the lower half of the left stellate
ganglion in 10 patients with long QT syndrome. They reported that
7 of the 10 developed perioperative Horner syndrome. Our
approach has been to transect the sympathetic chain up, at the
base of the stellate ganglion, and in the process remove all of the
interior radiating nerve fibers, which is, as you state, the location
that releases the highest concentration of norepinephrine. By per-
forming the procedure in this fashion, we are effectively elimi-
nating the morbidity risks associated with this procedure without
sacrificing the treatment efficacy.
Dr James Tweddell (Milwaukee, Wis). Thank you. It was a nice
presentation. And although I would agree with Dr Dearani that this
is not a simple extension of a thoracoscopic sympathectomy for
hyperhidrosis, it is probably closer to that than the operations typi-
cally performed by most of the people in this room. So, when we
have encountered this problem, we have actually asked our adult
thoracic surgery colleagues to help us with this procedure. They
have tremendous experience with this. And, I think it is easier
for us to work with them as a team approach rather than try to rein-
vent the wheel on these patients; I did enjoy your presentation
much.ery c January 2014
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DDr Hofferberth. Thank you much for your comments,
Dr Tweddell.
Dr Laureano Molins (Barcelona, Spain). We have experience
with sympathectomy or better clipping for hyperhidrosis mainly.
We have little experience, 5 or 6 cases with babies. It is difficult
to decide if the stellate ganglion should be removed or not because
we do not want to have those Horner syndromes.
I think that the theory is to transect the lower part of the stellate
ganglion, but it is not easy to respect the whole one. So, in fact, I
have not done it, to resect the stellate ganglion, and the percentage
of the patients that went well was similar, 75% to 80%.
But, I would like first to congratulate you for your elegant pre-
sentation and to talk a little bit about bilateral approach. Could this
bilateral approach reach a high level of success? I really do not
know. And we begin always with left side, of course. We go
through until T6. But, I would like to know not only your experi-
ence but your opinion on that.
Dr Hofferberth. Thank you for your comments and question.
At this point in time, the experience of performing a bilateral sym-
pathectomy is limited at our center; however, the reason we did
include the comment on the conclusion slide is that most recent
patients treated with VATS-LCSD at our center had undergone a
left-sided sympathectomy and remained symptomatic. In this
particular case, we then decided to proceed with a second opera-
tion to perform a right-sided sympathectomy, and since that
time, that patient has been completely arrhythmia free. It is, obvi-
ously, a limited experience to date. However, this may be a strategy
that should be considered further in the future.
Dr Carl Backer (Chicago, Ill). I have 2 questions. The first re-
lates to a patient of ours with ventricular tachycardia treated by our
chief of anesthesia with a temporary sympathetic nerve block in
the left neck. This completely cleared up the arrhythmia and
then we electively took the patient for a thoracoscopic sympathec-
tomy several days later. Do you have any experience with tempo-
rary nerve blocks in the neck as a predictive study for this patient
population?The Journal of Thoracic and CaDr Hofferberth. As far as I am aware, there has not been any
experience using that as a temporary measure.
Dr Backer.Yes, and it worked, it was unbelievable, it was night
and day.
The second question I have relates to the fact that some of these
children are pretty small and putting in an epicardial ACID is not
without issues. Can we use sympathectomy as the primary ther-
apy? We had one patient in whom we did the thoracoscopic sym-
pathectomy, the arrhythmias went away, and we observed the
child for a long time. We are still discussing whether or not we
should put in an AICD. Do you have patients in whom you
have simply done the sympathectomy and then not proceeded
with an AICD?
Dr Hofferberth. There are certainly patients that have had a
sympathectomy with additional medical treatment and who did
receive an ICD. We view this procedure as an adjunctive ther-
apeutic strategy that should always be implemented in conjunc-
tion with established therapies. In patients treated with
VATS-LCSD for primary prevention, we would still treat
them with optimal medical therapy; however, there have been
some patients who have been spared from undergoing ICD
implantation.
Dr Backer. I failed to mention we did treat this patient medi-
cally, and we did watch in the hospital for over a week. I noticed
your mean hospital stay was 2 days. How long would you watch
a patient with a sympathectomy and medical therapy before you
would send them out?
Dr Hofferberth. We discharge all patients on medical therapy
and then proceed to have them followed up regularly with a cardi-
ologist. So, at this point, a patient that has received a sympathec-
tomy is always going to be on some form of antiarrhythmic
therapy.
Dr Backer. Thank you much. This really was an eye-opening
presentation. This was not even on my radar screen 10 years
ago, and certainly it has now become an effective therapy. Thank
you much.rdiovascular Surgery c Volume 147, Number 1 411
